Ezurpimtrostat

Small molecule

Also known as GNS561

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Other / comorbidity
NCT05448677 · University Hospital, Grenoble
2022-12-15 – 2024-03-08 · Hepatocellular Carcinoma
What this study did
NCT04637828 · Genoscience Pharma
2020-11-18 – 2021-12-30 · COVID-19
What this study did
Phase 1/2 (2)
Cholangiocarcinoma with KRAS Mutation
Other / comorbidity
NCT03316222 · Genoscience Pharma
2018-04-04 – 2022-04-25 · Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
What this study did
Phase 1 (1)
Other / comorbidity
NCT05353894 · Genoscience Pharma
2022-05-02 – 2022-11-30 · Primary Liver Cancer
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ezurpimtrostat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 1/2Cholangiocarcinoma with KRAS MutationRecruiting
Est. primary completion 2027-12 · NCT05874414 · CT.gov ↗
What to watch

See the full readout calendar ↗